{"id":70711,"date":"2026-05-12T09:38:54","date_gmt":"2026-05-12T09:38:54","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70711"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"dsip","status":"publish","type":"product","link":"https:\/\/medsbase.com\/es\/product\/dsip\/","title":{"rendered":"DSIP"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Respuesta r\u00e1pida \u2014 \u00bfQu\u00e9 es el DSIP?<\/h3>\n<p style=\"margin: 0;\"><strong>DSIP<\/strong> (Delta Sleep-Inducing Peptide) is a 9-amino-acid neuropeptide first isolated from rabbit cerebral venous blood during electrical stimulation of thalamic sleep-promoting regions in 1977. In published studies it modulates sleep architecture \u2014 specifically slow-wave (delta) sleep \u2014 alongside documented effects on stress reactivity, withdrawal syndromes, and nociception. Supplied in 5\u00a0mg to 15\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Qu\u00e9 obtienes con MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/es\/reviews\/\">opiniones de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada pedido est\u00e1 cubierto por nuestra <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 si tu paquete no llega en 20 d\u00edas laborables, lo reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especificaci\u00f3n<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalle<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">62568-57-4<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>35<\/sub>H<sub>48<\/sub>N<sub>10<\/sub>O<sub>15<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">848.81 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE, 9 amino\u00e1cidos; lineal, extremos no modificados)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Polvo liofilizado (blanco a blanquecino)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA bajo solicitud)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Almacenamiento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (refrigerador) para stock de trabajo; \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. Reconstituido: 2\u20138 \u00b0C, usar dentro de ~30 d\u00edas. Proteger de la luz. No congelar-descongelar la soluci\u00f3n reconstituida.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidad<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Agua bacteriost\u00e1tica (recomendada) o agua est\u00e9ril para periodos de uso m\u00e1s cortos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u00bfQu\u00e9 es el DSIP?<\/h2>\n<p><strong>DSIP<\/strong> (Delta Sleep-Inducing Peptide) is a 9-amino-acid linear neuropeptide first isolated by Schoenenberger and Monnier at the University of Basel in 1977. The peptide was identified by dialysing cerebral venous blood from rabbits during electrical stimulation of the intralaminar thalamus \u2014 a region known to drive delta-wave (slow-wave) sleep in the cortex \u2014 and concentrating the bioactive fraction. DSIP was named for the dominant electroencephalographic signature it produced when administered to recipient animals: increased proportion of delta-wave activity during sleep. The well-characterised sequence is WAGGDASGE, molecular weight 848.81\u00a0Da, empirical formula C<sub>35<\/sub>H<sub>48<\/sub>N<sub>10<\/sub>O<sub>15<\/sub>. El DSIP es estructuralmente inusual entre los p\u00e9ptidos peque\u00f1os activos en el SNC \u2014es lineal, no modificado en ambos extremos y no contiene residuos de prolina o ciste\u00edna. El p\u00e9ptido se suministra como un polvo liofilizado de alta pureza para reconstituci\u00f3n con agua bacteriost\u00e1tica. El DSIP no est\u00e1 <strong>no est\u00e1 aprobado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For related circadian and sleep-axis peptide studies, see our <a href=\"https:\/\/medsbase.com\/es\/epitalon\/\">Epital\u00f3n<\/a> y <a href=\"https:\/\/medsbase.com\/es\/selank\/\">Selank<\/a> p\u00e1ginas de productos. <\/p>\n<h2>Mecanismo de acci\u00f3n \u2014 Arquitectura del sue\u00f1o, reactividad al estr\u00e9s y neuroprotecci\u00f3n<\/h2>\n<p>What makes DSIP unusual among peptides is the breadth of effects documented for such a small, linear peptide without a clearly identified primary receptor. Published studies has mapped its activity across <strong>tres dominios superpuestos<\/strong>, cada uno contribuyendo al fenotipo observado:<\/p>\n<ul>\n<li><strong>Modulaci\u00f3n de la arquitectura del sue\u00f1o \u2014 sue\u00f1o de ondas delta (sue\u00f1o de ondas lentas)<\/strong> \u2014 DSIP increases the proportion of slow-wave (stage 3\u20134 \/ N3) sleep on quantitative EEG measurements in rodent, rabbit, and human studies without proportionally reducing REM sleep. The effect is most pronounced when DSIP is administered to subjects with fragmented or shortened sleep, suggesting the peptide acts as a homeostatic sleep-pressure modulator rather than a primary sedative. Importantly, DSIP does not directly increase total sleep time in non-sleep-deprived subjects \u2014 it reorganises sleep architecture toward higher SWS proportion.<\/li>\n<li><strong>Modulaci\u00f3n del eje HPA y la reactividad al estr\u00e9s<\/strong> \u2014 M\u00faltiples estudios publicados documentan la atenuaci\u00f3n de la liberaci\u00f3n de cortisol y ACTH inducida por el estr\u00e9s en modelos de estr\u00e9s por restricci\u00f3n en roedores, junto con la reducci\u00f3n de la se\u00f1alizaci\u00f3n de la hormona liberadora de corticotropina (CRH) en el hipot\u00e1lamo. El efecto amortiguador del estr\u00e9s opera en una escala de tiempo m\u00e1s larga que los sedantes benzodiazep\u00ednicos y no produce sedaci\u00f3n conductual aguda, lo que sugiere una modulaci\u00f3n del tono del eje HPA en lugar de una ansiolisis aguda.<\/li>\n<li><strong>Anti-nocicepci\u00f3n, neuroprotecci\u00f3n y anti-abstinencia<\/strong> \u2014 DSIP shows analgesic effects in rodent thermal and chemical-nociception models, including opioid-naive subjects (suggesting non-opioid mechanism). Russian and Eastern European has documented attenuation of opioid and alcohol withdrawal syndromes in preclinical models. Neuroprotective effects against oxidative stress, ischaemia, and excitotoxicity have been reported but remain mechanistically less well characterised than the sleep architecture work.<\/li>\n<\/ul>\n<p>The receptor target for DSIP has not been definitively identified, which is unusual for a peptide with this much published behavioural data. Proposed mechanisms include GABA-A modulation, opioid-system crosstalk, and direct interaction with hypothalamic CRH neurons. The lack of an identified primary receptor combined with multiple documented effects suggests DSIP may act as a multimodal neuromodulator rather than a classical receptor agonist \u2014 a hypothesis that remains an active studies question in published peptide pharmacology. <\/p>\n<h2>Published Evidence<\/h2>\n<p>DSIP is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Sleep architecture and EEG studies<\/strong> \u2014 quantitative EEG spectral analysis, slow-wave sleep proportion, sleep fragmentation in rodent and human studies (Schoenenberger &amp; Monnier, PNAS 1977; Kovalzon &amp; Strekalova, Sleep Med Rev 2006)<\/li>\n<li><strong>Stress reactivity and HPA-axis studies<\/strong> \u2014 din\u00e1mica de cortisol y ACTH, expresi\u00f3n de CRH, modelos de estr\u00e9s por restricci\u00f3n y estr\u00e9s cr\u00f3nico leve en roedores<\/li>\n<li><strong>Withdrawal syndrome studies<\/strong> \u2014 gravedad de la abstinencia a opioides, abstinencia al alcohol, reducci\u00f3n gradual de benzodiazepinas; principalmente literatura publicada en Rusia y Europa del Este<\/li>\n<li><strong>Nociception and chronic pain studies<\/strong> \u2014 modelos de retirada de la cola, placa caliente, formalina y lesi\u00f3n por constricci\u00f3n cr\u00f3nica en roedores; caracterizaci\u00f3n del mecanismo no opioide<\/li>\n<li><strong>Neuroprotection studies<\/strong> \u2014 marcadores de estr\u00e9s oxidativo, lesi\u00f3n por isquemia-reperfusi\u00f3n, modelos de excitotoxicidad<\/li>\n<li><strong>Circadian biology studies<\/strong> \u2014 sincronizaci\u00f3n, respuesta al cambio de fase, modulaci\u00f3n del ritmo de melatonina y temperatura central<\/li>\n<li><strong>Comparative sleep-axis peptide studies<\/strong> \u2014 evaluaci\u00f3n comparativa frente a <a href=\"https:\/\/medsbase.com\/es\/epitalon\/\">Epital\u00f3n<\/a> (tetrap\u00e9ptido pineal) para efectos circadianos y contra <a href=\"https:\/\/medsbase.com\/es\/selank\/\">Selank<\/a> para efectos amortiguadores del estr\u00e9s sin sedaci\u00f3n.<\/li>\n<\/ul>\n<p>Para un contexto m\u00e1s amplio sobre d\u00f3nde encaja el DSIP en el panorama de los peque\u00f1os p\u00e9ptidos activos en el SNC, consulte <a href=\"https:\/\/medsbase.com\/es\/epitalon\/\">Epital\u00f3n<\/a> (AEDG pineal tetrapeptide, circadian-axis studies), <a href=\"https:\/\/medsbase.com\/es\/selank\/\">Selank<\/a> (heptap\u00e9ptido ansiol\u00edtico), y <a href=\"https:\/\/medsbase.com\/es\/semax\/\">Semax<\/a> (heptap\u00e9ptido nootr\u00f3pico). Explore el completo <a href=\"https:\/\/medsbase.com\/es\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para compuestos relacionados. <\/p>\n<h2>Concentraciones y potencias disponibles<\/h2>\n<p>MedsBase stocks DSIP in three lyophilized vial sizes covering pilot dosing through extended protocols. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Potencia del vial<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tama\u00f1os de paquete<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short protocols, pilot dosing, single-EEG-session studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, multi-week sleep-architecture studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>15 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo extendido, menor costo por mg, estudios de m\u00faltiples cohortes<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 o 30 viales<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols or run extended studies from a single vial. <\/p>\n<h2>C\u00f3mo se compara \u2014 DSIP vs Epitalon<\/h2>\n<p>DSIP y <a href=\"https:\/\/medsbase.com\/es\/epitalon\/\">Epital\u00f3n<\/a> are the two most-cited small peptides involved in sleep, circadian, and rest-state studies. They share several studies-relevant features \u2014 both are short, linear, unmodified peptides without identified primary receptors, and both produce phenotypic effects that outlast plasma clearance \u2014 but their primary signals are distinct: DSIP modulates sleep architecture directly via SWS proportion; Epitalon acts on the pineal-melatonin axis and circadian gene expression. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Criterio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">DSIP<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Epital\u00f3n<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longitud<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">9 amino\u00e1cidos (lineal)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4 amino\u00e1cidos (tetrap\u00e9ptido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Secuencia<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">WAGGDASGE<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">AEDG (Ala-Glu-Asp-Gly)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Primary signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Proporci\u00f3n de sue\u00f1o de ondas lentas (delta EEG)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pineal-melatonin axis, telomerase, circadian gene expression<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Identified receptor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">None (multimodal neuromodulator)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">None (gene-regulatory, intracellular)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dosis t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">100\u2013500\u00a0mcg, 1x daily<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">5\u201310\u00a0mg, 1x daily for cycles<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Effect onset<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Same-session (EEG measurable)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Multi-week (gene-expression timescale)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Combinaci\u00f3n<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Co-administered with Epitalon in circadian-sleep stack studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Co-administered with DSIP for combined sleep+circadian effects<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For sleep-architecture studies, DSIP is the canonical first choice because it produces measurable EEG-level effects on slow-wave sleep proportion within a single sleep session. For circadian-rhythm and gene-regulatory studies, Epitalon is preferred because the effect timescale matches the underlying biology (gene expression changes over days to weeks). The two are frequently co-administered when both axes are part of the studies question. <\/p>\n<h2>Almacenamiento y reconstituci\u00f3n<\/h2>\n<p><strong>Antes de la reconstituci\u00f3n:<\/strong> store lyophilized vials refrigerated at 2\u20138\u00a0\u00b0C in original packaging for short-term working stock. For unopened long-term storage, freeze at \u221220\u00a0\u00b0C. Lyophilized DSIP is stable under refrigeration for up to 24 months and at \u221220\u00a0\u00b0C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder. DSIP is hygroscopic \u2014 reseal vials promptly after opening and store in a desiccated container if available. <strong>Procedimiento de reconstituci\u00f3n:<\/strong> inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers a 100\u00a0mcg dose. Swirl gently \u2014 do <strong>ajuste<\/strong> shake \u2014 and allow 2\u20135 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless. <strong>Despu\u00e9s de la reconstituci\u00f3n:<\/strong> almacene refrigerado a 2\u20138 \u00b0C y util\u00edcelo dentro de los 30 d\u00edas para una estabilidad \u00f3ptima. No congele la soluci\u00f3n reconstituida: los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan la integridad del p\u00e9ptido. Deseche cualquier vial que muestre turbidez, precipitado o decoloraci\u00f3n. <\/p>\n<h2 id=\"faqs\">Preguntas frecuentes<\/h2>\n<h3>What is DSIP used for in studies?<\/h3>\n<p>DSIP is used in studies investigating sleep architecture (particularly slow-wave sleep proportion), HPA-axis and stress reactivity, opioid and alcohol withdrawal syndromes, non-opioid analgesia, neuroprotection, and circadian biology. It is the most-cited sleep-axis peptide that does not act primarily as a sedative \u2014 effects manifest as reorganisation of sleep architecture rather than increased total sleep time. The pharmaceutical-grade DSIP sold here is <strong>ajuste<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>How is DSIP different from Epitalon?<\/h3>\n<p>Both are small unmodified peptides without identified primary receptors that influence rest-state biology, but their primary signals differ. DSIP modulates sleep architecture at the EEG level \u2014 specifically increasing slow-wave sleep proportion within a single sleep session. Epitalon acts on the pineal-melatonin axis and circadian gene expression on a gene-expression timescale of days to weeks. The two are mechanistically complementary and frequently co-administered in studies investigating combined sleep and circadian endpoints. <\/p>\n<h3>What is the typical DSIP dose?<\/h3>\n<p>Los protocolos precl\u00ednicos publicados suelen utilizar 100\u2013500 mcg por administraci\u00f3n en modelos de roedores, administrados por v\u00eda subcut\u00e1nea o intraperitoneal una vez al d\u00eda durante ciclos de 7\u201328 d\u00edas. Un vial de 5 mg reconstituido con 2,0 mL de agua bacteriost\u00e1tica produce una concentraci\u00f3n de 2,5 mg\/mL \u2014 0,04 mL equivalen a 100 mcg. <\/p>\n<h3>\u00bfEst\u00e1 el DSIP aprobado por la FDA?<\/h3>\n<p>No. DSIP is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. <\/p>\n<h3>\u00bfC\u00f3mo se debe almacenar el DSIP?<\/h3>\n<p>Viales liofilizados: refrigerados a 2\u20138 \u00b0C para stock de trabajo a corto plazo, o a \u221220 \u00b0C para almacenamiento a largo plazo de viales sin abrir. El DSIP es higrosc\u00f3pico \u2014 vuelva a sellar los viales inmediatamente despu\u00e9s de abrirlos. Soluci\u00f3n reconstituida: refrigerada a 2\u20138 \u00b0C, usar dentro de los 30 d\u00edas. No congele la soluci\u00f3n reconstituida \u2014 los ciclos de congelaci\u00f3n-descongelaci\u00f3n degradan el p\u00e9ptido. Proteja siempre de la luz directa. <\/p>\n<h3>\u00bfC\u00f3mo reconstituyo el DSIP?<\/h3>\n<p>Siga el procedimiento de reconstituci\u00f3n anterior. A\u00f1ada agua bacteriost\u00e1tica por la pared lateral del vial (no sobre el polvo liofilizado), agite suavemente y permita de 2 a 5 minutos para la disoluci\u00f3n completa. No <strong>ajuste<\/strong> agite el vial. Una soluci\u00f3n correctamente reconstituida es transparente e incolora. Para un vial de 5 mg + 2,0 mL de diluyente, la concentraci\u00f3n de trabajo es de 2,5 mg\/mL. <\/p>\n<h3>\u00bfQu\u00e9 concentraciones tiene MedsBase en stock?<\/h3>\n<p>MedsBase carries DSIP in 5\u00a0mg, 10\u00a0mg, and 15\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Does DSIP cause sedation in study models?<\/h3>\n<p>No \u2014 this is one of the most-cited findings in DSIP studies. Unlike benzodiazepines or other classical sedatives, DSIP does not produce acute behavioural sedation, motor coordination loss, or impaired alertness. Instead it modulates sleep architecture toward a higher proportion of slow-wave sleep when the subject does sleep, without increasing total sleep time in non-sleep-deprived subjects. This distinct profile is one of the reasons DSIP has remained a compound rather than a clinical sedative. <\/p>\n<h3>Can DSIP and Epitalon be stacked in studies?<\/h3>\n<p>Yes. DSIP and Epitalon act on different timescales and biological compartments (acute EEG-level sleep architecture vs gene-expression-level circadian regulation), so co-administration is not pharmacologically redundant. Study protocols studying combined sleep-quality and circadian-rhythm endpoints frequently use both peptides. <\/p>\n<h3>Does DSIP cause side reported effects?<\/h3>\n<p>Published preclinical studies has reported a notably clean safety profile at typical doses, with no consistent sedation, motor-coordination effects, dependence liability, or rebound on discontinuation. Long-term human safety data is limited because the peptide has not undergone modern Western regulatory review. The small size and lack of identified primary receptor are consistent with the clean tolerability profile. <\/p>\n<h3>\u00bfCu\u00e1l es la vida media del DSIP?<\/h3>\n<p>In preclinical studies, DSIP has a plasma half-life of approximately 7\u201315 minutes following intravenous or subcutaneous administration. The short plasma half-life is offset by the peptide&#8217;s ability to cross the blood-brain barrier and produce effects on sleep architecture and gene expression that persist well beyond plasma clearance. <\/p>\n<h3>\u00bfPor qu\u00e9 se aisl\u00f3 originalmente el DSIP?<\/h3>\n<p>El DSIP fue identificado en 1977 por Schoenenberger y Monnier en la Universidad de Basilea mediante di\u00e1lisis de sangre venosa cerebral de conejos durante la estimulaci\u00f3n el\u00e9ctrica del t\u00e1lamo intralaminar \u2014 una regi\u00f3n cerebral conocida por inducir el sue\u00f1o de ondas delta (sue\u00f1o de ondas lentas). Concentraron la fracci\u00f3n bioactiva y caracterizaron el p\u00e9ptido que produc\u00eda el efecto m\u00e1s fuerte en el EEG del sue\u00f1o cuando se transfer\u00eda a animales receptores. El p\u00e9ptido fue nombrado por su firma electroencefalogr\u00e1fica dominante: aumento de la actividad de ondas delta durante el sue\u00f1o. <\/p>\n<h3>How long does DSIP take to show effects in preclinical studies?<\/h3>\n<p>Los efectos agudos en la arquitectura del sue\u00f1o y la proporci\u00f3n de ondas delta en el EEG son detectables durante la primera sesi\u00f3n de sue\u00f1o tras la administraci\u00f3n. Los efectos en el eje HPA y la reactividad al estr\u00e9s se acumulan tras 7\u201314 d\u00edas de dosificaci\u00f3n regular. Los efectos anti-abstinencia en modelos de abstinencia de opioides y alcohol suelen medirse durante per\u00edodos de abstinencia de 3\u20137 d\u00edas. <\/p>\n<h3>\u00bfPuedo pedir DSIP para env\u00edo internacional?<\/h3>\n<p>S\u00ed. MedsBase env\u00eda DSIP a todo el mundo desde nuestra red de env\u00edos dedicada a p\u00e9ptidos. Los pedidos que solo contienen p\u00e9ptidos califican para nuestro servicio de env\u00edo exclusivo para p\u00e9ptidos. Todos los pedidos se env\u00edan en embalaje con control de temperatura con seguimiento completo y est\u00e1n cubiertos por nuestro <a href=\"https:\/\/medsbase.com\/es\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Sleep, Circadian, and CNS Studies<\/h2>\n<ul>\n<li><a href=\"\/es\/epitalon\/\"><strong>Epital\u00f3n<\/strong><\/a> \u2014 AEDG pineal tetrapeptide \u2014 pineal-melatonin axis and circadian gene-expression studies<\/li>\n<li><a href=\"\/es\/selank\/\"><strong>Selank<\/strong><\/a> \u2014 Anxiolytic heptapeptide tuftsin analog \u2014 GABA\/BDNF stress resilience<\/li>\n<li><a href=\"\/es\/semax\/\"><strong>Semax<\/strong><\/a> \u2014 Heptap\u00e9ptido nootr\u00f3pico desarrollado en Rusia \u2014 modulaci\u00f3n melanocortina y dopamin\u00e9rgica<\/li>\n<li><a href=\"\/es\/oxytocin-acetate\/\"><strong>Oxitocina Acetato<\/strong><\/a> \u2014 9-aa cyclic nonapeptide \u2014 social-bonding and affiliative behavioural support<\/li>\n<li><a href=\"\/es\/bpc-157\/\"><strong>BPC-157<\/strong><\/a> \u2014 Body Protection Compound \u2014 healing and tissue-recovery<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Lecturas adicionales<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore sleep, circadian, and CNS peptides<\/strong><\/p>\n<p style=\"margin: 0;\">Explora toda la <a href=\"https:\/\/medsbase.com\/es\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, con compuestos relacionados que incluyen <a href=\"https:\/\/medsbase.com\/es\/epitalon\/\">Epital\u00f3n<\/a> for circadian gene-expression studies, <a href=\"https:\/\/medsbase.com\/es\/selank\/\">Selank<\/a> for anxiolytic stress-axis studies, and <a href=\"https:\/\/medsbase.com\/es\/oxytocin-acetate\/\">Oxitocina Acetato<\/a> for social-bonding behavioural support.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 P\u00e9ptido inductor del sue\u00f1o delta (descubierto en 1977)<br \/>\n\u2705 Modula la arquitectura del sue\u00f1o de ondas lentas<br \/>\n\u2705 HPA-axis stress reactivity<br \/>\n\u2705 Efectos antiabstinencia y analgesia no opioide<br \/>\n\u2705 Cruza la barrera hematoencef\u00e1lica<\/p>\n<p><strong>DSIP<\/strong> contiene compuesto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70946,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6275,5441],"class_list":["post-70711","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-dsip","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product\/70711","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/comments?post=70711"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media\/70946"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/media?parent=70711"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_brand?post=70711"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_cat?post=70711"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/es\/wp-json\/wp\/v2\/product_tag?post=70711"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}